Johnson & Johnson Receives FDA Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform

In July 2026, Johnson & Johnson MedTech received U.S. Food and Drug Administration (FDA) approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a novel catheter ablation method intended to treat atrial fibrillation and other heart arrhythmias. By combining radiofrequency and pulsed field ablation technologies into a single device, the recently approved platform allows doctors to select the best energy source for surgery without having to change catheters. The approval offers more flexibility and accuracy for minimally invasive cardiac therapies, which is a significant step in electrophysiology.

Millions of people worldwide are still affected by cardiac arrhythmias, which are still a leading cause of heart failure, stroke, and other cardiovascular problems. One of the best ways to restore a normal heart rhythm is now catheter ablation, especially for people who don't react well to medication. Physicians are looking for cutting-edge technology that enhances treatment accuracy while streamlining clinical procedures as procedural complexity keeps rising to meet these changing therapeutic needs. Johnson & Johnson created the Dual Energy platform, which combines two complementary ablation methods into a single system.

Depending on the patients' health and procedure requirements, the platform allows physicians to administer either radiofrequency or pulsed field radiation. While pulsed to specifically target heart tissue with little effect on neighboring structures, radiofrequency ablation produces controlled thermal lesions to remove aberrant electrical pathways. More procedural flexibility and more individualized treatment plans for complicated cardiac arrhythmias are supported by the capacity to switch between the two energy sources during a single procedure.

The Dual Energy THERMOCOOL SMARTTOUCH SF Platform is completely compatible with Johnson & Johnson's TRUPILSETM Generator and CARTOTM 3 Mapping System, enabling doctors to monitor lesion formation and catheter contact force in real time while performing sophisticated three-dimensional cardiac mapping. Throughout the ablation process, this integrated approach facilitates better clinical decision-making, increases treatment precision, and improves procedural visualization. The startup wants to increase workflow efficiency in electrophysiology labs by integrating mapping navigation and dual energy delivery into a single platform.

The well-known THERMOCOOL SMARTTOUCH SF catheter, which has been extensively utilized in cardiac ablation operations over the previous ten years. Is the foundation of the recently authorized technology Johnson & Johnson enhancing its electrophysiology portfolio and giving doctors more treatment options that may be tailored to various clinical situations by adding pulsed-field ablation to the platform? The industry's increasing emphasis on creating integrated technologies that enhance procedural results and operational efficiency is also reflected in the approval.

The launch of the Dual Energy platform demonstrates how technical advancements are continuously changing cardiac electrophysiology. To improve patient outcomes while lowering procedure complexity, healthcare providers are increasingly implementing sophisticated mapping systems, clever catheter technology, and minimally invasive treatment approaches. Integrated ablation platforms are anticipated to become more significant in the future of cardiovascular treatment as the need for safer and more individualized cardiac therapies grows.

With its most recent FDA approval, Johnson & Johnson reaffirms its dedication to developing electrophysiology by providing cutting-edge technologies that help doctors manage complicated heart rhythm abnormalities. It is anticipated that the platform will increase therapeutic potential, enhance procedural flexibility, and support the ongoing advancement of minimally invasive cardiovascular care.

Impact on the Healthcare Industry

According to Precedence Research, innovation in the healthcare sector is being fueled by the rising incidence of cardiovascular diseases and the rising need for minimally invasive treatment methods. Advanced electrophysiological technologies that increase procedural accuracy, improve patient safety, and streamline clinical processes are being used by hospitals and cardiac care facilities more often. This trend is supported by the FDA clearance of Johnson & Johnson's Dual Energy THERMOCOOL SMARTTOUCH SF Platforms, which offer doctors an integrated solution that combines pulsed-field and radiofrequency ablation in one system. It is anticipated that these technical developments will improve treatment outcomes, strengthen cardiovascular care, and hasten the adoption of next-generation cardiac intervention technology.

Impact on the Cardiac Ablation Market

The global cardiac ablation market size was calculated at USD 5.79 billion in 2025 and is predicted to increase from USD 5.79 billion in 2025 to approximately USD 21.84 billion by 2035, expanding at a CAGR of 14.20% from 2025 to 2035.

According to the Precedence Research, the market for cardiac ablation is expanding because of the increased prevalence of atrial fibrillation and other cardiac arrhythmias as well as the growing need for minimally invasive procedures. This trend is further supported by the FDA clearance of the Johnson & Johnson Dual Energy THERMOCOOL SMARTTOUCH SF Platform, which allows doctors to utilize a single catheter for both radiofrequency and pulsed field ablation. It is anticipated that the combination of dual energy technology with a sophisticated cardiac mapping system will boost treatment accuracy, increase procedural efficiency, and promote the broader use of catheter ablation techniques in healthcare institutions.

Impact on the Electrophysiology Devices Market

The global electrophysiology devices market size accounted for USD 14.55 billion in 2025 and is predicted to reach around USD 55.43 billion by 2035 and is poised to grow at a CAGR of 14.31% from 2026 to 2035.

According to Precedence Research, increasing markets are expanding due to rising investments in cutting-edge cardiac rhythm management technology and ongoing advancements in electrophysiology systems. The increasing trend toward integrated electrophysiological solutions that enhance clinical flexibility and procedural outcomes is exemplified by the recently approved Dual Energy THERMOCOOL SMARTTOUCH SF Platform. The technology is anticipated to help the ongoing development of minimally invasive cardiac care and hasten the adoption of next-generation electrophysiological devices by integrating sophisticated mapping, contract force sensing, and dual energy ablation capabilities onto a single platform.

Expert Opinion

“The FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform marks an important milestone in expanding treatment options for physicians performing catheter ablation procedures. By offering both radiofrequency and pulsed field energy through a single platform, we aim to provide greater procedural flexibility while supporting improved patient care," said Johnson & Johnson MedTech.”

About Johnson & Johnson MedTech

Johnson & Johnson MedTech creates cutting-edge medical technologies for orthopedic surgery, cardiovascular care, and vision through integrated medical devices, digital technology, and data-driven solutions that enhance clinical results. The company focuses on advancing minimally invasive procedures. Johnson & Johnson MedTech provides healthcare providers with cutting-edge technologies that improve patient care and procedure efficiency via ongoing investments in research and product innovation.